The purpose of this study is to compare the usual treatment (cytarabine and daunorubicin) to each of the study treatments: daunorubicin and cytarabine liposome; cytarabine and daunorubicin with venetoclax; azacitidine and venetoclax; and daunorubicin and cytarabine liposome with venetoclax .
Learn more about the MyeloMATCH MM1YA-S01 trial or call the Reading Hospital Cancer Research Office at 484-628-8193.
